Who buys pcrx stock?
PCRX stock was bought by a variety of institutional investors in the last quarter, including Paulson & CO. Inc., Stonnington Group LLC, Baillie Gifford & Co., Hodges Capital Management Inc., Schroder Investment Management Group, Frontier Capital Management Co. LLC, Russell Investments Group Ltd., and Assenagon Asset Management S.A..
When will pcrx earnings call for 2019?
PCRX earnings call for the period ending December 31, 2019. PCRX earnings call for the period ending September 30, 2019. PCRX earnings call for the period ending June 30, 2019. Invest better with The Motley Fool.
Is Pacira Biosciences (Paci) stock a good buy?
Pacira BioSciences has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 6 buy ratings, 2 hold ratings, and no sell ratings. According to analysts' consensus price target of $82.50, Pacira BioSciences has a forecasted upside of 28.3% from its current price of $64.32.
Is Pcrx a buy?
Is Pacira Biosciences Stock a good buy in 2022, according to Wall Street analysts? The consensus among 5 Wall Street analysts covering (NASDAQ: PCRX) stock is to Strong Buy PCRX stock.
Is Pacira a public company?
Pacira went public on February 3, 2011 at a price of $7.00 per share.
How many employees does pacira pharmaceuticals have?
750 employeesBased in Parsippany-Troy Hills, NJ, Pacira BioSciences is a medium-sized pharmaceutical company with 750 employees and a revenue of $429.6M. To improve patient care through low or no opioid strategies with specific injection techniques.
Is pacira a good company to work for?
Is Pacira Pharmaceuticals a good company to work for? Pacira Pharmaceuticals has an overall rating of 3.0 out of 5, based on over 106 reviews left anonymously by employees. 37% of employees would recommend working at Pacira Pharmaceuticals to a friend and 38% have a positive outlook for the business.
Should I buy or sell Pacira BioSciences stock right now?
7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Pacira BioSciences in the last twelve months. There are...
What is Pacira BioSciences' stock price forecast for 2022?
7 Wall Street analysts have issued 1-year price objectives for Pacira BioSciences' stock. Their forecasts range from $60.00 to $96.00. On average,...
How has Pacira BioSciences' stock price performed in 2022?
Pacira BioSciences' stock was trading at $60.17 at the beginning of the year. Since then, PCRX shares have decreased by 7.2% and is now trading at...
When is Pacira BioSciences' next earnings date?
Pacira BioSciences is scheduled to release its next quarterly earnings announcement on Tuesday, August 2nd 2022. View our earnings forecast for Pa...
How were Pacira BioSciences' earnings last quarter?
Pacira BioSciences, Inc. (NASDAQ:PCRX) announced its earnings results on Wednesday, May, 4th. The company reported $0.64 EPS for the quarter, missi...
What guidance has Pacira BioSciences issued on next quarter's earnings?
Pacira BioSciences issued an update on its first quarter 2022 earnings guidance on Tuesday, April, 26th. The company provided earnings per share (E...
Who are Pacira BioSciences' key executives?
Pacira BioSciences' management team includes the following people: Mr. David M. Stack , Chairman & CEO (Age 72, Pay $1.59M) ( LinkedIn Profile )...
What is Dave Stack's approval rating as Pacira BioSciences' CEO?
54 employees have rated Pacira BioSciences CEO Dave Stack on Glassdoor.com . Dave Stack has an approval rating of 45% among Pacira BioSciences' em...
Who are some of Pacira BioSciences' key competitors?
Some companies that are related to Pacira BioSciences include Johnson & Johnson (JNJ) , Pfizer (PFE) , Eli Lilly and (LLY) , AbbVie (ABBV) , M...
When will Pacira Biosciences release its earnings?
How much does Pacira Biosciences make?
Pacira BioSciences is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021. View our earnings forecast for Pacira BioSciences.
What is Pacira Biosciences Inc?
Pacira BioSciences has a market capitalization of $2.50 billion and generates $429.65 million in revenue each year. The company earns $145.52 million in net income (profit) each year or $1.30 on an earnings per share basis.
What time do you trade in the pre market?
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for health care practitioners and their patients. The company has launched EXPAREL which utilizes DepoFoam, a product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time.
Does market cap include convertible securities?
Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is strictly voluntary and as a result, these sessions may offer less liquidity and inferior prices. Stock prices may also move more quickly in this environment.
What is Pacira Biosciences?
It does not include securities convertible into the common equity securities. "Market Cap" is derived from the last sale price for the displayed class of listed securities and the total number of shares outstanding for both listed and unlisted securities (as applicable).
Where is Pacira Biosciences located?
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for health care practitioners and their patients in the United States. The company develops products based on its proprietary DepoFoam product delivery technology that encapsulates drugs without altering their molecular structure. It offers EXPAREL, a bupivacaine liposome injectable suspension, administered at the time of surgery to control pain and reduce or eliminate the use of opioids for acute postsurgical pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled doses of cold temperature only to targeted nerves. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Parsippany, New Jersey.
